A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  American Journal of Human Genetics

• Publication date

  2007-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1086/521032PMID 17924331PMCID PMC2265654
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.

  2007cited by this paper
• Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information

  2007cited by this paper
• Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.

  2006cited by this paper
• Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.

  2006cited by this paper
• Functional Impact of Missense Variants in BRCA1 Predicted by Supervised Learning

  2006cited by this paper
• The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in Lynch syndrome

  2006cited by this paper
• Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2

  2006cited by this paper
• Cancer risk assessment at the atomic level.

  2006cited by this paper
• Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.

  2005cited by this paper
• Classification of BRCA1 missense variants of unknown clinical significance

  2005cited by this paper
• An Analysis of Unclassified Missense Substitutions in Human BRCA1

  2005cited by this paper
• Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.

  2005cited by this paper
• Classification of Missense Mutations of Disease Genes

  2005cited by this paper
• Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants

  2005cited by this paper
• Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral

  2005cited by this paper
• Structure-Based Assessment of Missense Mutations in Human BRCA1

  2004cited by this paper
• Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.

  2004cited by this paper
• Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation

  2004influential reference
• The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.

  2004cited by this paper
• Methods to Classify BRCA1 Variants of Uncertain Clinical Significance: The More the Merrier

  2004cited by this paper
• A full-likelihood method for the evaluation of causality of sequence variants from family data.

  2003cited by this paper
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

  2003influential reference
• Biallelic Inactivation of BRCA2 in Fanconi Anemia

  2002cited by this paper
• BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.

  2002cited by this paper
• The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

  2002cited by this paper
• A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage

  2001cited by this paper
• Understanding human disease mutations through the use of interspecific genetic variation.

  2001cited by this paper
• Prediction of deleterious human alleles.

  2001cited by this paper
• Missense mutations in disease genes: a Bayesian approach to evaluate causality.

  1998cited by this paper
• Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.

  1997cited by this paper
• Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2

  1997cited by this paper
• Evidence for a transcriptional activation function of BRCA1 C-terminal region.

  1996cited by this paper
• Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities

  1996cited by this paper
• Transcriptional activation by BRCA1

  1996cited by this paper
• Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13.

  1995cited by this paper
• Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wild–type chromosome

  1992cited by this paper
• Strategies for multilocus linkage analysis in humans.

  1984cited by this paper
• Amino Acid Difference Formula to Help Explain Protein Evolution

  1974cited by this paper

• Challenges of Real-World Utilization of Recommendations From ClinGen ENIGMA: A Focus on BRCA2 Variant Classification in Chinese Population.

  2026cites this paper
• WHO HAS TO UNDERGO CANCER GENETIC TESTING? A PERSPECTIVE.

  2026cites this paper
• Identification of Fowler syndrome (hydrocephaly-hydranencephaly proliferative vasculopathy) in a pregnancy following single euploid embryo transfer

  2025cites this paper
• Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system

  2025cites this paper
• Calibration and refinement of ACMG/AMP criteria for variant classification with BayesQuantify

  2025cites this paper
• The Time Lag Associated With the Reclassification of Germline BRCA Variants' Pathogenicity Is Critical for Cancer Patients

  2025cites this paper
• Saturation genome editing-based clinical classification of BRCA2 variants

  2025influential citation
• Rare genetic associations with human lifespan in UK Biobank are enriched for oncogenic genes

  2025cites this paper
• Availability of benign missense variant "truthsets" for validation of functional assays: Current status and a systematic approach.

  2025cites this paper
• Precision screening facilitates clinical classification of BRCA2-PALB2 binding variants with benign and pathogenic functional effects

  2025cites this paper
• When two plus four does not equal six: Combining computational and functional evidence to classify BRCA1 key domain missense substitutions.

  2025cites this paper
• Assessment of BRCA1 and BRCA2 Germline Variant Data From Patients With Breast Cancer in a Real-World Data Registry

  2024cites this paper
• Reinterpretation of Conflicting ClinVar BRCA1 Missense Variants Using VarSome and CanVIG-UK Gene-Specific Guidance

  2024cites this paper
• Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset.

  2024cites this paper
• BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer

  2024cites this paper
• Challenges and approaches to calibrating patient phenotype as evidence for cancer gene variant classification under ACMG/AMP guidelines.

  2024cites this paper
• Proline variants in the BRCA1 coiled‐coil domain disrupt folding and binding to PALB2

  2024cites this paper
• Saturation genome editing of 11 codons and exon 13 of BRCA2 coupled with chemotherapeutic drug response accurately determines pathogenicity of variants

  2023cites this paper
• Actionability classification of variants of unknown significance correlates with functional effect

  2023cites this paper
• Inter-BRCT linker is probably the most intolerant region of the BRCA1 BRCT domain

  2023cites this paper
• Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes

  2023cites this paper
• Rosetta Energy Analysis of AlphaFold2 models: Point Mutations and Conformational Ensembles

  2023cites this paper
• A Likelihood Ratio Approach for Utilizing Case-Control Data in the Clinical Classification of Rare Sequence Variants: Application to BRCA1 and BRCA2

  2023cites this paper
• Sequencing-based functional assays for classification of BRCA2 variants in mouse ESCs

  2023cites this paper
• Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study

  2023cites this paper
• Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1/2 variant carriers in Japan

  2023cites this paper
• Functional Analyses of Rare Germline Missense BRCA1 Variants Located within and outside Protein Domains with Known Functions

  2023cites this paper
• Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers

  2022cites this paper
• BRCA1 Variant Assessment Using a Simple Analytic Assay.

  2022cites this paper
• Value of the loss of heterozygosity to BRCA1 variant classification

  2022cites this paper
• Value of the loss of heterozygosity to BRCA1 variant classification

  2022cites this paper
• DisPhaseDB, an integrative database of diseases related variations in liquid-liquid phase separation proteins

  2022cites this paper
• Characterization of Synonymous BRCA1:c.132C>T as a Pathogenic Variant

  2022cites this paper
• How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?

  2022cites this paper
• Computational Biology of BRCA2 in Male Breast Cancer, through Prediction of Probable nsSNPs, and Hit Identification

  2022cites this paper
• Can AlphaFold2 predict the impact of missense mutations on structure?

  2022cites this paper
• An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance

  2022cites this paper
• Multiparametric and accurate functional analysis of genetic sequence variants using CRISPR-Select

  2022cites this paper
• Spectrum and management of breast cancer patients with variant of uncertain significance mutations at a tertiary care centre in North India

  2022cites this paper
• Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions.

  2022cites this paper
• BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: looking for the hidden meaning.

  2022cites this paper
• Assessment of small in-frame indels and C-terminal nonsense variants of BRCA1 using a validated functional assay

  2022cites this paper
• Evaluation of conformational transitions of h-BRCA2 functional domain and unclassified variant Arg2502Cys using multimodal approach.

  2022cites this paper
• In Silico and Structure-Based Assessment of Similar Variants Discovered in Tandem Repeats of BRCT Domains of BRCA1 and BARD1 To Characterize the Folding Pattern

  2022cites this paper
• Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2

  2022cites this paper
• DisPhaseDB: An integrative database of diseases related variations in liquid–liquid phase separation proteins

  2022cites this paper
• Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants: Application of a points‐based ACMG/AMP approach

  2022influential citation
• The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series

  2021cites this paper
• Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance

  2021cites this paper
• Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean

  2021cites this paper
• An updated quantitative model to classify missense variants in the TP53 gene: A novel multifactorial strategy

  2021cites this paper
• Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes—Practice resource of the National Society of Genetic Counselors

  2021cites this paper
• Functional evidence (I) transcripts and RNA-splicing outline

  2021cites this paper
• A Validated Functional Analysis of PALB2 (Partner and Localizer of BRCA2) Missense Variants for Use in Clinical Variant Interpretation.

  2021cites this paper
• Quantitative modeling

  2021cites this paper
• A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study

  2021cites this paper
• 5′ Region Large Genomic Rearrangements in the BRCA1 Gene in French Families: Identification of a Tandem Triplication and Nine Distinct Deletions with Five Recurrent Breakpoints

  2021cites this paper
• Quality and Quantity: How to Organize a Countrywide Genetic Counseling and Testing

  2021cites this paper
• Breast cancer risks associated with missense variants in breast cancer susceptibility genes

  2021cites this paper
• Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.

  2021cites this paper
• Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules

  2021cites this paper
• Clinical consequences of BRCA2 hypomorphism

  2021cites this paper
• Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

  2021cites this paper
• Phenotype evaluation and clinical context

  2021cites this paper
• Implications of the germline variants of DNA damage response genes detected by cancer precision medicine for radiological risk communication and cancer therapy decisions

  2021cites this paper
• Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.

  2021cites this paper
• Cancer-causing BRCA2 missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance

  2021cites this paper
• First international workshop of the ATM and cancer risk group (4-5 December 2019)

  2021cites this paper
• Classification of genetic variants in hereditary cancer genes

  2021cites this paper
• Risikoadaptierte Prävention bei familiär bedingtem Brust- und Eierstockkrebs

  2020cites this paper
• Homologous recombination-deficient cancers: approaches to improve treatment and patient selection

  2020cites this paper
• Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance

  2020cites this paper
• Policy strategies for personalising medicine “in the data moment”

  2020cites this paper
• A likelihood‐based approach to assessing frequency of pathogenicity among variants of unknown significance in susceptibility genes

  2020cites this paper
• Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays

  2020cites this paper
• Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines

  2020cites this paper
• Tissue-Specific Carcinogens as Soil to Seed BRCA1/2-Mutant Hereditary Cancers.

  2020cites this paper
• A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays

  2020cites this paper
• Cancer Genomics in Precision Oncology: Applications, Challenges, and Prospects

  2020cites this paper
• 'Essentials of Cancer Genomic, Computational Approaches and Precision Medicine

  2020cites this paper
• High-throughput functional evaluation of BRCA2 variants of unknown significance

  2020cites this paper
• Homologous recombination-deficient cancers: approaches to improve treatment and patient selection

  2020cites this paper
• Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer

  2020cites this paper
• Human Mutation

  2020cites this paper
• Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation

  2020cites this paper
• Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide

  2020cites this paper
• BRCA GENES MUTATIONS’ OF HEREDITARY BREAST CANCER IN CRIMEA

  2020cites this paper
• Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network

  2020cites this paper
• Incorporation of semi‐quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes

  2019cites this paper
• GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes

  2019cites this paper
• Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants An

  2019influential citation
• Patients' perspectives of variants of uncertain significance and strategies for uncertainty management

  2019cites this paper
• Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation

  2019cites this paper
• Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.

  2019cites this paper
• Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification.

  2019cites this paper
• Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants

  2019cites this paper
• Exploring the effect of ascertainment bias on genetic studies that use clinical pedigrees

  2019cites this paper
• Rare variant phasing using paired tumor:normal sequence data

  2019cites this paper
• Significant Strain Variation in the Mutation Spectra of Inbred Laboratory Mice

  2019cites this paper
• Curated multiple sequence alignment for the Adenomatous Polyposis Coli (APC) gene and accuracy of in silico pathogenicity predictions

  2019cites this paper